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Abstract
Type 2 diabetes and obesity epidemics are in effect in the United States and the two pathologies are linked. In
accordance with the growing appreciation that ‘exercise is medicine,’ it is intuitive to suggest that exercise can play
an important role in the prevention and/or treatment of these conditions. However, if exercise is to truly be
considered as a viable alternative to conventional healthcare prevention/treatment strategies involving pharmaceuticals, it
must be prescribed with similar scrutiny. Indeed, it seems reasonable to posit that the recent initiative calling for ‘precision
medicine’ in the US standard healthcare system should also be applied in the exercise setting. In this narrative review, we
consider a number of explanations that have been forwarded regarding the pathological progression to type 2 diabetes
both with and without the concurrent influence of overweight/obesity. Our goal is to provide insight regarding exercise
strategies that might be useful as ‘precision medicine’ to prevent/treat this disease. Although the etiology of type 2
diabetes is complex and cause/consequence characteristics of associated dysfunctions have been debated, it is well
established that impaired insulin action plays a critical early role. Consequently, an exercise strategy to prevent/treat this
disease should be geared toward improving insulin sensitivity both from an acute and chronic standpoint. However,
research suggests that a chronic improvement in insulin sensitivity only manifests when weight loss accompanies an
exercise intervention. This has resonance because ectopic fat accumulation appears to represent a central component of
disease progression regardless of whether obesity is also part of the equation. The cause/consequence characteristics of
the relationship between insulin resistance, pathological fat deposition and/or mobilsation, elevated and/or
poorly-distributed lipid within myocytes and an impaired capacity to use lipid as fuel remains to be clarified as
does the role of muscle mitochondria in the metabolic decline. Until these issues are resolved, a multidimensional
exercise strategy (e.g., aerobic exercise at a range of intensities and resistance training for muscular hypertrophy) could
provide the best alternative for prevention/treatment.
Keywords: Type 2 diabetes, Insulin resistance, Obesity, Intramyocellular lipid, Mitochondrial dysfunction, Ectopic lipid
accumulation, Metabolically-healthy obesity, Fatmax, Critical power/velocity, High-intensity interval training
Introduction
Recent statistics indicate that 23.1 million people (7.2% of
the population) in the US have diabetes with another 7.2
million afflicted, but not diagnosed [1]. The vast majority
possess type 2 diabetes (T2D), a disorder that is linked
with the ‘American obesity epidemic.’ Moreover, ~ 34% of
American adults have prediabetes, which means they are
at increased risk for developing T2D and comortalities in-
cluding heart disease and stroke [1]. Indeed, estimates are
that 25% of those diagnosed with prediabetes will have
T2D within 3–5 years. The end result is that diabetes was
responsible for ~ 12% of deaths in the US in 2010 making
it the third leading cause of mortality in the country [2].
With respect to treating both symptom and cause, the
association between T2D and obesity is important to ex-
plore. Overweight/obesity is a well-established risk factor
that accounts for 80–85% of the likelihood of developing
T2D [3, 4]. However, while most individuals with T2D are
obese, most obese individuals do not develop T2D despite
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demonstrating an impaired capacity for insulin-regulated
gluco/lipometabolism in target organs/tissues (i.e., insulin
resistance; IR) [5]. Furthermore, there is a growing body of
research exploring atypical patients for whom the obesity/
IR association is disjointed; for example, obese individuals
with normal insulin sensitivity (IS) [6–8] and individuals
with IR who are not overweight [9–11] (i.e., ‘metabolically--
healthy obese’ and ‘metabolically-unhealthy normal weight,’
respectively). Finally, T2D has even been reported in
non-obese subjects without IR due to deficiencies in insulin
secretion [12, 13]. Collectively, these observations regarding
distinct subsets of metabolically-compromised individuals
(see Fig. 1) reflect the highly complex and multifactorial
aetiology of T2D in obese and non-obese individuals.
In 2007, a health initiative was launched jointly by the
American Medical Association (AMA) and American
College of Sports Medicine (ACSM) [14]. Termed ‘Exer-
cise is Medicine,’ the premise was that instead of a
healthcare system based on ‘sick care,’ the focus should
be on preservation and promotion of health with exer-
cise playing a major role [14]. Needless to say, with the
aforementioned epidemics in effect and this sentiment
resonating throughout the field, a considerable amount
of recent research has been directed toward defining the
role that exercise can play in treating IR and delaying/
preventing its progression to T2D. This appears appro-
priate because physical inactivity has been identified as
one of six risk factors for complications of T2D for US
adults [1]. However, while it is intuitive to believe that ex-
ercise can benefit the health profile of these patients, there
is evidence to suggest that exercise per se might not be
enough. For example, some studies have shown that
chronic aerobic training does not improve IR unless hypo-
caloric intake and corresponding weight loss accompanies
the intervention [15]. Moreover, IR can be improved by
surgical removal of body fat [16, 17], which means that it
is the alteration in fat deposition, as opposed to chronic
negative energy balance per se, that is the stimulus that
drives the associated improvement. Therefore, in the
absence of weight loss, the degree to which chronic
aerobic training and/or resistance training (RT) can influ-
ence the pattern of fat deposition both in adipose [18] and
muscle [19] tissue is an important factor to consider.
The purpose of this article is to review research explor-
ing the role that chronic exercise training can play in the
prevention/treatment of IR and its progression to T2D. In
doing so, we will pay particular attention to the link
between obesity and T2D with emphasis devoted to the
metabolically-healthy obese and metabolically-unhealthy
normal-weight phenotypes that serve to dissociate the two
pathophysiologies. We will also explore the strong genetic
predisposition for IR in the offspring of individuals with
T2D (FH+). An underlying theme will be addressing the
ongoing debate regarding the role of muscle mitochondria
in the pathological progression.
Review of exercise as precision medicine for insulin
resistance and its progression to type 2 diabetes
Insulin-resistant Glucose Metabolism
Generally speaking, T2D involves a combination of IR
and inadequate insulin secretion to adequately compen-
sate [20]. The progression to T2D has been suggested to
comprise five definitive stages with IR initiating a patho-
logical decline that requires years or even decades to
complete [21]. The critical role of IR in this sequence is
exemplified by the fact that it underpins the strong gen-
etic predisposition for T2D [22] with FH+ demonstrat-
ing marked IR long before glucose tolerance becomes
impaired [23, 24]. Indeed, in accordance with this gen-
etic link, IR has been advanced as a significant contribu-
tor to the T2D progression [25]. In stage 1, IR begins
when insulin-sensitive target tissues (e.g., skeletal
muscle, liver and adipocytes) begin to demonstrate a
decreased response to the regulatory prowess of the cir-
culating hormone. Particularly relevant in this regard is
skeletal muscle, which represents the predominant site
of insulin-stimulated glucose disposal in the body. At
this early stage of disease progression, the measurement
of C-peptide (a byproduct of insulin production that ex-
ists in equal amount) concentration in blood or urine
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Fig. 1 Prevalence of insulin resistance, obesity and type 2 diabetes in the US adult population. The complex interaction between insulin resistance,
overweight/obesity and type 2 diabetes is exemplified by five distinct subsets of metabolically-compromised individuals that collectively comprise >
50% of the US adult population (grey shade). The fact that some of these individuals can fend off metabolic decline despite being obese while others
possess type 2 diabetes and/or insulin resistance without obesity provides evidence that initiation and progression of type 2 diabetes is multi-factorial
and complex. IS, insulin sensitive; IR, insulin resistant; T2D, type 2 diabetes; NW, normal weight; O, obese
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might provide a useful way to identify the need for a
prophylactic exercise intervention. Fortunately, in this ini-
tial ‘compensation’ stage, increased insulin secretion
(hyperinsulinemia) secondary to an increase in pancreatic
β-cell mass/productivity allows for maintenance of
homeostatic levels of plasma glucose. Left unaddressed,
however, the chronic overload associated with this ‘quick
fix’ takes its toll and β-cells become dysfunctional [26]
with glucose-stimulated insulin secretion ultimately re-
duced (stage 2) [21]. The resultant hyperglycemia con-
tinues the pathological progression and allows for the
diagnosis of prediabetes via measurement of fasting
plasma glucose and/or hemoglobin A1c (i.e., tests that
identify elevations in plasma-glucose concentration). With
the passage of time, β-cell function continues to decline
with increasing IR (stage 3) causing a cascade of events
(stage 4) that ultimately culminates in T2D (stage 5) [21].
Type 2 diabetes as a disease of lipid metabolism
With IR and resultant hyperglycemia playing a critical
role in the pathological progression to T2D, it is not sur-
prising that the disease is considered one of aberrant
glucose metabolism. However, for prevention/treatment
purposes, it might be short-sighted to define diabetes as
a disease of carbohydrate metabolism alone. Indeed,
there is growing support for an ‘alternative angle’ offered
in 1992 when J. Denis McGarry asked the whimsical
question, ‘What if Minkowski had been ageusic?’ [27]. In
his opinion piece, McGarry speculated a series of events
based on Randle’s substrate-competition model [28]
whereby an increase in lipid oxidation would inhibit glu-
cose use. Within this schema, IR-induced hyperinsuline-
mia and resultant liver lipogenesis and synthesis of
very-low-density lipoproteins (VLDL) would serve to in-
crease the flux of triglycerides into storage sites includ-
ing muscle (intramyocellular lipid; IMCL) thereby
interfering with normal glucose processing. The end re-
sult would be an elevation of plasma glucose that com-
pletes a vicious cycle of aberrant fuel partitioning [27].
McGarry’s contention that the pathophysiological mech-
anisms of IR and hyperglycemia should be considered off-
shoots of dysfunctional lipid metabolism is supported by a
number of more recent observations. For example, using
nuclear magnetic resonance spectroscopy, Krssak et al.
confirmed an inverse relationship between IS and plasma
free fatty acid concentration (FA) during fasting in
normal-weight adults without T2D [29]. Importantly, an
inverse relationship was also found between IS and IMCL
in this study [29]. Similarly, Perseghin et al. used nuclear
magnetic resonance spectroscopy to show that in lean
insulin-resistant FH+ (i.e., a group at high risk for devel-
oping the disease [30]), the main predictors of whole-body
IS were FA and intramyocellular triglyceride content
(IMTG; i.e., the predominant component of IMCL) [31].
Interestingly, a similar association between IMTG and IR
was reported independent of total-body adiposity in Pima
Indian men without T2D, a group that is predisposed to
obesity and development of the disease [32]. Finally, longi-
tudinal studies involving dietary interventions that in-
crease [33] or decrease [34] lipid storage confirm an
inverse relationship between IMCL and IS. The reason for
this link between elevated IMCL and IS is unclear, but
likely reflects a ‘lipotoxic’ chain of events initiated by lipid
metabolites (e.g., long-chain fatty acyl-CoA, ceramides,
sphingosine-1-phosphate and some diacylglycerol species)
which activate a serine-kinase cascade that desensitises
insulin receptors [35–38].
The paradox of IMTG accumulation
While it is attractive to implicate the lipotoxic effects of
metabolites that accompany elevated IMCL as the precur-
sor of IR, it is important to note that endurance-trained
subjects who demonstrate high IS also have elevated IMCL
[35, 39–41]. A likely explanation for this ‘athlete’s paradox’
is that both energy turnover and the capacity to satisfy en-
ergetic requirements via lipid oxidation are markedly
greater for endurance-trained compared to untrained sub-
jects. Consequently, it is the degree to which IMCL is used
as opposed to storage per se that appears responsible for
pathological repercussion when stores are elevated. In this
regard, Stannard and Johnson advance a teleological model
of IR based on the contention that it represents a functional
adaptation that occurs in response to chronic energy sur-
plus [42]. Their reasoning is based on the ‘thrifty-genotype
hypothesis,’ which posits a hunter/gatherer phenotype for
which periods of food abundance are inevitably followed by
periods of food scarcity [42]. During the latter periods,
elevations in IMCL and reductions in IS that develop
during the former provide for an easily-accessed energy
source and conservation of glucose, respectively [42, 43].
However, when the food-scarcity component is removed
from the equation for the untrained individual (e.g., as is
the case in the present day with food procurable without
significant energetic outlay and hunting and gathering
having been replaced by sitting and lying down), IMTG
stores are not adequately used, glucose is preserved in
abundance and the response to energetic surplus that had
been functional becomes pathological. Endurance athletes
avoid this consequence by maintaining a physically-active
(and, therefore, physiologically ‘normal’) lifestyle. Given our
increasingly sedentary existence and the associated increase
in likelihood of hyperenergetic intake, evaluation of this
athletic phenotype appears particularly relevant.
Skeletal muscle mitochondrial dysfunction in patients
with type 2 diabetes
While the association between family history and T2D is
strong, how the majority of the inherited risk is conveyed
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remains to be determined [44]. Although environmental
factors dictated by parental input (e.g, diet and physical ac-
tivity) cannot be discounted, if IR is a significant
contributor to the T2D progression and metabolites associ-
ated with elevated IMCL beget IR, the cause of pathological
IMCL accumulation might be a significant factor respon-
sible for passing the predisposition for T2D in some cases.
In accordance with basic supply/demand dynamics, it is in-
tuitive that excess IMCL accumulation could result from
an overabundance of FA availability/uptake to/by muscle
and/or insufficient FA oxidation within muscle. While the
former could play a role [45, 46], most research interest has
been devoted to the latter with evidence suggesting that pa-
tients with T2D demonstrate a reduced capacity for lipid
oxidation during the fasting [47, 48], postprandial [47] and
exercise [49] conditions. Consequently, as the organelles re-
sponsible for lipid oxidation, skeletal muscle mitochondria
have been implicated as potential culprits. Specifically, the
reduced capacity for lipid oxidation could result from
‘mitochondrial dysfunction;’ for example, decreased mito-
chondrial biogenesis, reduced mitochondrial content and/
or decreased protein content/activity of oxidative en-
zymes per unit mitochondria [50]. Support for this conten-
tion comes from Simoneau and Kelley who used
percutaneous biopsy of the vastus lateralis to confirm lower
oxidative-enzyme activity in subjects with T2D compared
to counterparts without the disease [51]. Moreover, the ra-
tio of glycolytic-to-oxidative enzymes was negatively corre-
lated with IS with the ratio of citrate synthase to
hexokinase providing the strongest correlation [51]. Abnor-
mal hexokinase activity has also been implicated in IR [52].
In a follow-up study, Kelley et al. also obtained muscle bi-
opsies and found lower overall respiratory-chain activity
and smaller intermyofibrillar mitochondria (i.e., the
mitochondrial subpopulation that provides energy for
muscle contractile activity [53]) in the group with
T2D with each of these decrements positively corre-
lated with the severity of IR [54]. In a similar study,
Ritov et al. isolated mitochondrial subpopulations and
found that respiratory-chain activity for patients with
T2D was particularly compromised in the subsarco-
lemmal subpopulation, the fraction that provides
energy for insulin-signaling processes like signal
transduction, ion exchange and substrate transport/ac-
tivation [55]. In this study, patients with T2D also
demonstrated decreased subsarcolemmal mitochon-
drial content; however, importantly, this reduction did
not fully explain the decrease in activity [55]. Finally,
Mogensen et al. induced state-3 respiration with
pyruvate plus malate in fully-coupled isolated mito-
chondria and maximal respiration through the elec-
tron transport chain to confirm a reduction in
function per mitochondrion for patients with T2D
compared to subjects that did not possess the disease
[56]. Moreover, the values were associated with
HbA1c measurement, which is consistent with a link
between mitochondrial dysfunction and the chronic
elevation of blood-glucose concentration that the
HbA1c measurement identifies [56].
A T2D-related deficit attributable to a reduction in
mitochondrial functional capacity, as opposed to content
per se, is an important finding because it is consistent
with the notion that mitochondria convey the inherent
defect that predisposes T2D. However, there are a num-
ber of caveats when interpreting observations from these
investigations. In all cases, the patients with T2D were
also obese, which is important because obesity adversely
affects mitochondrial function independent of T2D sta-
tus. For example, in three of the four studies, three
groups were included for comparison such that the ef-
fect of obesity without T2D could be isolated and in
these studies, the decrements observed for the obese
subjects with T2D were also present for the obese sub-
jects without the disease although reductions in overall
[52, 54] and subsarcolemmal [55] activity were greater
when obesity was accompanied by the disease. It is also
insightful to note that Oberbach et al. report a
fiber-specific ratio of glycolytic-to-oxidative enzyme
activity that was not different for patients with T2D
compared to healthy control subjects matched for age-
and body mass index (BMI) [57]. However, patients with
T2D demonstrated a 16% reduction and 49% increase in
slow-oxidative and fast-glycolytic fiber fraction, respect-
ively [57]. Although the authors’ use of glycerol-3-
phosphate dehydrogenase as a marker of glycolytic
enzyme activity can be questioned, this finding is
consistent with the contention that T2D could be a
disease of fiber-type distribution as opposed to mito-
chondrial function per se.
In addition to the potential influence of obesity and
fiber-type distribution that might accompany T2D, it is
important to recognise that a reduction in mitochondrial
function with T2D is not a universal finding to begin
with. For example, Boushel et al. observed a decrease in
electron-transport capacity for obese subjects with T2D
that was totally attributable to a decrease in mitochon-
drial content [58]. The authors reasoned that mitochon-
drial compromise was, therefore, not a cause, but a
consequence of T2D [58] or, more specifically, the low
level of physical activity that subjects with T2D typically
experience [59–61]. This suggestion is supported by lon-
gitudinal studies involving training interventions that
improve mitochondrial content in patients with T2D
[62, 63]. Similarly, mitochondrial defects might be a con-
sequence of T2D-related energetic alterations; for
example, hyperglycemia- and hyperlipidemia-induced
production of reactive oxygen species (ROS) [64]. Fi-
nally, the degree to which any deficit in lipid-oxidising
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capacity that might be present for subjects with T2D
could create a pathological accumulation of IMCL has
also been questioned because healthy mitochondrial cap-
acity greatly outstrips oxidative demand. Consequently, a
significant reserve capacity exists such that lipid oxida-
tion by patients with T2D should not be limited during
their everyday tasks (e.g., during the resting state and for
the types of physical activities that would be typical for
these patients) [65].
Skeletal muscle mitochondrial function and insulin
resistance
Ambiguity regarding the underlying meaning of any
mitochondrial deficiency that accompanies T2D makes
it impossible at present to determine whether such defi-
ciency precipitates the elevated IMCL associated with
development of the disease. However, findings from
studies of IR individuals that do not yet possess diabetes
provide important insight. For example, Petersen et al.
found that young, lean FH+ with severe IR demonstrate
an ~ 80% greater IMCL content and an ~ 30% lower
basal rate of mitochondrial ATP synthesis with similar
rate of lipolysis compared to insulin-sensitive control
subjects matched for age, height, weight and activity
level [66]. In a follow-up study, these researchers
reported that a reduced rate of mitochondrial ATP syn-
thesis was also present for these subjects during
insulin-stimulated conditions (hyperinsulinemic-euglyce-
mic clamp) with flux only increasing by ~ 5% of the
basal rate compared to ~ 90% for control subjects [67].
Finally, in another follow-up study, Morino et al. found
that FH+ had an ~ 38% lower mitochondrial density
compared to control subjects [68]. Collectively, these ob-
servations are consistent with the suggestion that IMCL
accumulates to pathological levels and induces IR when
muscle mitochondria cannot adequately ‘move’ all of the
IMCL that is stored.
With respect to dysfunctional mitochondrial lipid oxi-
dation as the ‘inherent defect’ of IR (and, by extension,
T2D), the findings by Petersen and colleagues are com-
pelling because the link was established in subjects who
were young and not overweight. Consequently, the asso-
ciation could not be attributed to confounding factors
like long-term hypoenergetic activity level, chronic
hyperenergetic intake and/or resultant obesity. However,
it is important to recognise that these subjects were
already demonstrating severe IR due to their genetic pre-
disposition; hence, implications regarding the develop-
ment of IR from this research is only speculative. For
example, it has been shown that insulin influences mito-
chondrial ATP production by increasing mRNA levels
from mitochondrial and nuclear genes that encode mito-
chondrial proteins [69]. Consequently, the mitochondrial
defects that were observed for FH+ might have been a
consequence as opposed to cause of the severe IR that
was inherent for these individuals. It is, therefore,
important to also consider findings from longitudinal
studies where mitochondrial lipid-oxidising capacity
and IS were the independent and dependent variables,
respectively. For example, Short et al. had healthy
previously-sedentary subjects aged 22–87 years per-
form 16 weeks of aerobic training that increased the
peak rate of oxygen consumption (V̇O2peak/max; i.e.,
the gold-standard index of oxidative capacity), activity
of muscle mitochondrial enzymes and mRNA levels
of mitochondrial genes and genes involved in mito-
chondrial biogenesis to a similar extent for all age
groups [70]. However, a ‘chronic’ improvement in IS
(i.e., increased IS measured ≥96 h after the final train-
ing session) was only observed for the ‘younger’ sub-
jects (i.e., aged 20–39 years), which was surprising
because the younger subjects also had the smallest
window for improvement (IS decreased ~ 8% per dec-
ade in this cohort) [70]. This lack of effect of aerobic
training on IS despite similar improvement in mito-
chondrial function for middle-age/older subjects
argues against a mitochondrial deficit in the decline
of IS at least that which occurs with aging. Con-
versely, as for the IR associated with FH+, Østergård
et al. had sedentary subjects aged 20–50 years per-
form 10 weeks of aerobic training and found that
V̇O2peak, oxidative-enzyme activity and IS improved to
a similar extent in FH+ subjects with IR and controls
[71]. These findings for genetic- compared to
age-related IR support the notion of a mitochondrial
deficit for the former and again highlight the complex
aetiology of the condition. However, while Østergård
et al. did find that IS was correlated with V̇O2max at
baseline and after 10 weeks of training and that
training-induced improvements in V̇O2max were
strongly correlated with increased IS, these correla-
tions were present in the control group only [71].
Conversely, for FH+, no such associations were
present and, furthermore, AT-induced changes in IS
were not correlated with changes in oxidative-enzyme
activity in either group [71]. Finally, in a study
designed to assess IR in the presence of pharmaco-
logical manipulation of mitochondrial capacity,
Lagouge et al. showed that Resveratrol, a
naturally-occurring activator of NAD-dependent dea-
cetylase sirtuin-1 and, by extension, peroxisome
proliferator-activated receptor γ coactivator (a gene
associated with mitochondrial biogenesis; PGC-1 α),
increases mitochondrial content while also protecting
against diet-induced IR in treated mice [72].
In addition to training and pharmacological studies
undertaken to assess the association between improve-
ments in mitochondrial function and IS, a number of
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longitudinal studies have been designed to test the link
between mitochondrial decline and development of IR.
In one such study, Fleischman et al. reported an ~ 52%
decline in mitochondrial DNA/nuclear DNA that was
accompanied by a reduction in IS in healthy volunteers
exposed to 30 days of administration of the
HIV-infection medication stavudine, which is a nucleo-
side reverse transcriptase inhibitor that carries with it
the side effect of mitochondrial toxicity [73]. However,
these alterations were not correlated and IMCL (i.e., the
proposed intermediate between reduced mitochondrial
capacity and IR) was not increased by the intervention
[73]. Conversely, Pospisilik et al. found that IS was
compensatorily increased in mice after deletion of
muscle- and liver-specific mitochondrial flavoprotein
apoptosis-inducing factors which created a deficiency in
respiratory-chain function that mimicked that which is
present in human IR [74]. Moreover, an FA-raising
high-fat diet that induced IR in rats also resulted in a
compensatory increase in PGC-1 α and other mitochon-
drial proteins [75]. Although not a universal finding [76],
it has been suggested that it is this fat-induced
up-regulation of mitochondrial lipid-oxidising capacity
and consequent ‘excessive lipid oxidation’ that begets IR
due to increased mitochondrial stress, incomplete
fatty-acid breakdown and excessive production of ROS
[77–79]. Within this schema, it is the resultant loss of
insulin responsiveness that causes the mitochondrial
dysfunctionality that is typically observed alongside T2D
[69, 80].
The ‘metabolic inflexibility’ of obesity
Ongoing debate regarding the underyling meaning of
the mitochondrial deficiency observed for patients
with T2D and FH+ subjects underscores the complex
aetiology of the loss of IS that characterises these
conditions. However, even greater complexity is
present when overweight/obesity is part of the patho-
physiology. In a landmark study, Kelley et al. mea-
sured glucose and FA uptake across the leg alongside
indirect calorimetry and found that in both lean and
obese subjects, the rate of FA uptake in the basal
state (i.e., at rest after an overnight fast) exceeded FA
oxidation [81]. This means that regardless of body
composition, net storage of IMCL was taking place.
Furthermore, the rate of FA uptake was similar be-
tween lean and obese subjects. However, lipid oxida-
tion was less for obese subjects, which meant that the
net storage of IMCL was greater compared to their
normal-weight counterparts [81]. This observation,
which suggests that it is the ability to use IMCL that
is responsible for IMCL accumulation for obese sub-
jects, lead Kelley et al. to label an impairment in skel-
etal muscle fatty-acid utilisation as a ‘primary defect’
predisposing (as opposed to resulting from) obesity
[81]. Kelley et al. also found a significant negative
correlation between leg respiratory quotient (RQ; i.e.,
the ratio of the rate of CO2 production to V̇O2,
which reflects substrate proportionality with values
ranging from 0.7 to 1.0 for exclusive lipid and carbo-
hydrate oxidation, respectively) and IS, which sup-
ports a link between perturbed metabolism of FA and
insulin-resistant glucose metabolism [81].
In addition to a reduction in lipid oxidation in the
basal state (i.e., during a condition where lipid use
should predominate to protect plasma-glucose concen-
tration), Kelley et al. also found that obese subjects did
not effectively suppress lipid oxidation during
insulin-stimulated conditions. Specifically, during a
hyperinsulinemic euglycemic clamp, leg RQ was virtually
unchanged from the fasting state (~ 0.90). This is the
hallmark of IR. Conversely, for lean subjects, RQ fluctu-
ated from ~ 0.83 to ~ 0.99 for basal and insulin stimula-
tion, respectively [81]. The authors suggest that the
‘metabolic flexibility’ required to appropriately switch
between lipid and carbohydrate fuels represents a critical
characteristic of healthy metabolic function that is ab-
sent with obesity [81, 82].
Kelley et al. contended that an impaired capacity for
lipid oxidation is the primary defect of obesity based on
the metabolic inflexibility they observed for obese sub-
jects in the basal state [81]. Consequently, researchers
began using the difference in RQ across the extremes
established during the hyperinsulinemic euglycemic
clamp procedure (ΔRQclamp-fast or ΔNPRERclamp-fast
when non-protein respiratory exchange ratio at the
mouth is used for the measurement) to evaluate the
functionality of substrate switching in different types
of subjects [83–86]. However, there have been chal-
lenges to the use of both the ‘floor’ and ‘ceiling’ of
this measurement for unveiling the underlying cause
of metabolic dysfunction. For example, concerns have
been raised regarding the degree to which other
factors influence basal lipid oxidation. Specifically,
Galgani et al. explain that energy balance, macronutri-
ent composition and the substrate content of plasma
can all affect the rate of basal lipid oxidation inde-
pendent of metabolic functionality [87]. Moreover, it
is intuitive that basal energy requirements represent a
modest metabolic challenge; hence, the absolute rate
of lipid oxidation will be low under basal conditions
even when metabolic function is preserved and the
relative rate of lipid oxidation is high. Therefore, it is,
perhaps, the capacity for lipid oxidation during more
metabolically-challenging conditions that will more
faithfully reveal a defect that sets T2D progression in
motion. A dietary-fat overload provides one such
challenge [87].
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Metabolic flexibility in response to diet
As previously mentioned, ingestion of a high-fat diet and
consequent elevation of plasma FA results in a compen-
satory decrease in glucose uptake/oxidation by inducing
what might be considered a ‘functional’ IR [27, 28, 42,
88]. Accordingly, the ability to rapidly up-regulate lipid
oxidation in response to high-fat feeding would be pre-
dicted to protect IS while a sluggish capacity for such
adaptation could predispose IR and, ultimately, T2D.
Findings from a number of investigations support this
contention. For example, Heilbronn et al. compared FH
+ (i.e., subjects with a strong predisposition for T2D) to
age- and fatness-matched individuals with no family his-
tory of T2D (FH-) and found that RER increased to a
similar extent after a high-carbohydrate meal for both
groups [89]. However, FH+ had an impaired ability to
reduce RER following ingestion of a high-fat (76%) meal
and this difference was present despite similar IS, fasting
lipid oxidation and postprandial plasma FA across
groups [89]. Importantly, these researchers also observed
between-group differences for activation of PGC-1 α and
fatty-acid translocase (FAT/CD36; i.e., a
mitochondrial-membrane protein involved in the trans-
port of long-chain FA), which is consistent with a gen-
etic predisposition for the impaired response that they
observed [89]. Moreover, Ukropcova et al. exposed FH+
and FH- to chronic iso-energetic high-fat (50%) feeding
and found that FH+ had a greater sleep RER after three
days [90]. They also found that sleep RER in response to
the baseline diet that was maintained prior to the
three-day period (35% fat) was negatively correlated with
IS, which supports an association between the ability to
oxidise lipid and maintenance of insulin responsiveness
[90]. Finally, Berk et al. assessed substrate oxidation after
eucaloric switches from low- (30%) to high- (50%) and
high- to low-fat diets and found that Caucasian women
demonstrated an increased rate of lipid oxidation, de-
creased rate of carbohydrate oxidation and decreased
RER seven days after increasing fat intake [91]. Con-
versely, substrate oxidation for African-American
women (i.e., a group predisposed to IR and T2D [92])
after the high-fat switch remained fixed. Consequently,
African-American women demonstrated a lower rate of
lipid oxidation after chronic high-fat intake (181 ± 12
and 231 ± 12 μmol·min− 1 for African-American and
Caucasian women, respectively) while Caucasian women
also achieved a higher rate of carbohydrate oxidation
after switching from high- to low-fat intake [91]. Collect-
ively, these findings are consistent with a difference in
metabolic flexibility between these two groups and,
importantly, these differences remained significant after
adjusting for age, waist-to-hip ratio, BMI, percent body
fat, fat-free mass, fat mass and adipose-tissue areas (i.e.,
visceral and subcutaneous deposits). These observations
underscore the genetic root of this impairment [89] and
this metabolic inflexibility in response to diet resonates
when you consider the high-fat content of the standard
American diet and the degree to which such a diet likely
contributes to the high incidence of obesity [93].
The metabolic inflexibility of type 2 diabetes
Given the reduction in metabolic flexibility that FH+
and T2D-predisposed subjects experience in response
to dietary manipulations [89–91], it is not surprising
that patients with T2D also demonstrate dysfunctional
substrate switching. For example, van de Weijer et al.
found that RER was higher in the basal state and
lower during the insulin-stimulated condition for
subjects with T2D compared to age- and
BMI-matched controls [85]. This confirmed that the
subjects with T2D in their study were metabolically
inflexible (see Fig. 2). They also used 31P magnetic
resonance spectroscopy to show that the phospho-
creatine recovery half-time (PCr t1/2) following five
minutes of knee-extensor exercise was ~ 12.5% slower
for the patients with T2D [85]. According to the
model of respiratory control proposed by Meyer, PCr
kinetics serves as a proxy for V̇O2 kinetics and, there-
fore, provides a measure of oxidative capacity such
that a slower response is consistent with impaired
mitochondrial function in vivo [94]. Interestingly, van
de Weijer et al. also found that PCr t1/2 was the only
significant predictor of basal RER while whole-body
glucose-disposal rate was the only predictor of RER
during the insulin-stimulated condition [85]. The lat-
ter is consistent with the observation that in patients
with T2D, the metabolic inflexibility to glucose during
insulin stimulation is exclusively attributable to a de-
creased rate of glucose availability consequent to an
‘upstream’ disposal rate limitation and, possibly, an
inability of insulin to effectively suppress plasma FA
[95]. Moreover, these findings help to explain why
weight loss improves insulin-stimulated aspects of
metabolic flexibility in obese subjects while what
appears to be a deeper-seated lipid-related impairment
remains unaltered [95]. Indeed, the lowered ceiling
that reduces ΔNPRERclamp-fast (i.e., the decreased
NPRERclamp) appears to be a consequence as opposed
to cause of T2D while the inadequate up-regulation
of fasting lipid oxidation that elevates the floor (i.e.,
increases NPRERfast) is present in predisposed sub-
jects regardless of development of the disease [95].
Reports of an association between the capacity to oxi-
dise lipid in the basal state and IR for both FH+ [96]
and a pooled group of insulin-sensitive and
insulin-resistant subjects without T2D [97] also
support this contention. Collectively, these findings
suggest that NPRERfast alone might be a more
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important measurement to consider. However, as pre-
viously mentioned, using NPRERfast to determine the
degree to which the capacity to oxidise lipid is im-
paired has also been questioned [87].
Lipid oxidation during exercise
In addition to reporting an inverse association between
sleep RQ and IS in a group of FH+ and FH- subjects
(see above), Ukropcova et al. found that sleep RQ was
inversely related to mitochondrial DNA content [90].
However, both groups had a similar decrease in 24-h RQ
following the carbohydrate-to-lipid dietary switch and
no association between 24-h RQ and mitochondrial
DNA content was observed [90]. This means that if a
mitochondrial defect was responsible for the metabolic
inflexibility demonstrated by FH+, it was only identifi-
able during sleep, which is difficult to reconcile given
the benign metabolic challenge that is present under
those circumstances [87]. Conversely, exercise presents a
significant challenge to metabolic function that might
make it a more appropriate test for functional substrate
selectivity. Specifically, it is well established that under
normal circumstances, lipid and carbohydrate provide
the predominant fuels during aerobic exercise with the
relative contribution of each varying markedly depend-
ing upon substrate availability and the intensity and dur-
ation of the exercise challenge at hand. With regard to
intensity, Romijn et al. used stable isotope tracers and
indirect calorimetry to evaluate how endogenous fat and
glucose metabolism during exercise change with increas-
ing intensity (25, 65 and 85% V̇O2max) and found that
for five trained cyclists, plasma glucose uptake and
muscle glycogen oxidation increased with exercise inten-
sity [98]. This intensity-dependent increase in carbohy-
drate use contrasted reliance on peripheral lipolysis,
which was highest at the lowest intensity with FA release
into plasma decreasing at the more intense work rates.
However, IMTG lipolysis was stimulated only at the
higher intensities. The net effect was that the overall rate
of lipid utilisation increases with increasing intensity up
to a point after which it decreases and ultimately be-
comes negligible at the highest work rates (see Fig. 3
Top Panel) [98, 99]. The rate of carbohydrate oxidation
increases with increasing intensity in a similar manner;
however, in this case, the increase continues such that
the relative contribution of carbohydrate outstrips that
of lipid (i.e., a ‘crossover’ occurs) once high-intensity
efforts are encountered [98, 99] (see Fig. 3 Bottom
Panel). In accordance with this reciprocity, the ability to
oxidise lipid at a high rate during exercise and, therefore,
delay the switch from lipid to carbohydrate predomin-
ance might be the functionally-significant capacity that
an early-intervention program should be designed to de-
tect and improve.
The maximal capacity for lipid oxidation and insulin
sensitivity
To quantify the capacity to up-regulate lipid oxidation
during exercise, the intensities aligned with the maximal
rate of lipid oxidation (‘fatmax’) and the crossover point
to predominant carbohydrate oxidation during incre-
mental exercise have recently become variables of inter-
est. For example, in 2002, Achten and colleagues











Fig. 2 The metabolic inflexibility of type 2 diabetes. Metabolic flexibility is often quantified as the change in non-protein respiratory exchange
ratio between metabolic extremes; for example, the fasting state and the metabolic milieu created by supraphysiological insulin stimulation during a
hyperinsulinemic euglycemic clamp. In their study, van de Weijer et al. confirmed that subjects with type 2 diabetes demonstrate a higher NPRER (less
lipid use) during fasting (open bars) and a lower NPRER (less carbohydrate use) during maximal insulin stimulation (closed bars) [83]. Consequently,
these patients demonstrate metabolic inflexibility (reduced ΔNPRERclamp-fast; grey bars) compared to their non-diseased counterparts
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fatmax occurred at ~ 65% V̇O2max with lipid-oxidation
rates within 10% of this peak occurring from ~ 55–72%
[100]. Conversely, lipid use became negligible above ~
89% V̇O2max [98]. In a follow-up study, Venables et al.
assessed 300 healthy subjects and found that fatmax
occurred at 48.3 ± 0.9% of V̇O2max [101]. This estab-
lished a standard that could prove useful for identifying
metabolically at-risk individuals. For example, Robinson
et al. assessed 53 young, healthy, recreationally-active
men (fatmax at 58 ± 17% V̇O2max; range, 21–83%) and
found that the maximal lipid oxidation rate (expressed
in grams per minute) was positively correlated with IS
while V̇O2max and IS shared no such association [102].
Furthermore, in a longitudinal analysis, Venables et al.
showed that after four weeks of aerobic training, eight
sedentary obese, but otherwise healthy individuals expe-
rienced an ~ 44% increase in lipid-oxidation rate during
the 30-min exercise bout that was positively associated
with the improvement in IS that was also induced by
training [103]. Collectively, these studies support the
contention that the maximal capacity for lipid oxidation
is linked to the IS status of a subject.
The maximal capacity for lipid oxidation and type 2
diabetes
If the development of IR is associated with a reduction
in the maximal capacity for lipid oxidation during exer-
cise, it would stand to reason that subjects with T2D
would demonstrate a markedly reduced fatmax. Interest-
ingly, a number of studies have been conducted to con-
firm this hypothesis, but results have been mixed. For
example, Ghanassia et al. compared sedentary subjects
with T2D to age-, sex- and BMI-matched sedentary con-
trols with normal glucose tolerance and found that both
the fatmax and crossover point occurred at a lower per-
centage in the patients with T2D (25 ± 1 v. 37 ± 2% and
24 ± 2 v. 39 ± 2% of the peak work rate, respectively)
[102]. Indeed, patients with T2D demonstrated a lower
lipid oxidation rate per fat-free mass at all five relative
exercise intensities that were assessed in that study (i.e.,
20, 30, 40, 50 and 60% of the peak work rate) [104]. An-
other indication of an impaired capacity for lipid oxida-
tion for patients with T2D comes from Suk et al., who
compared women with T2D with age-, sex- and
BMI-matched controls and found that T2D was
Fig. 3 The reciprocal relationship that exists between lipid and carbohydrate use during exercise of increasing intensity. Top panel: As exercise
work rate is increased during incremental exercise, the rate of lipid oxidation also increases to reach its maximum value at a mid-range intensity
before decreasing and becoming negligible as the highest achievable work rates are encountered. Bottom Panel: The combination of increasing
energy expenditure, increasing carbohydrate contribution and the reduced reliance on lipid (see above) as exercise intensity increases results in a
‘crossover’ point beyond which lipid is no longer the predominant fuel. WRpeak, peak work rate during incremental exercise
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associated with a lower fatmax (~ 34 v. ~ 52% of
V̇O2max) and lipid oxidation rate at fatmax (~ 0.38 v. ~
0.55 g·min− 1) [105]. Specifically, the rate of lipid oxida-
tion was lower at three of the five relative intensities that
were investigated (40, 50 and 60 of V̇O2max, but not 20
or 30%) [105]. Conversely, Mogensen et al. compared
patients with T2D to age-, BMI- and PA-matched FH-
controls with normal glucose tolerance and found that
both the maximal rate of lipid oxidation (~ 0.3 g·min− 1)
and fatmax (~ 40% V̇O2max) were not different between
groups [106]. Furthermore, while fatmax was positively
correlated with V̇O2max, it did not show any association
with insulin-stimulated glucose disappearance rate (Rd)
[106]. In addition, following 10 weeks of aerobic training,
fatmax increased to a similar extent in T2D and control
group (~ 50% and ~ 40% of V̇O2max, respectively) with
the change not correlated with the increase in Rd that
also occurred due to training [106]. Given the import-
ance of determining whether the maximal rate of lipid
oxidation and fatmax are, indeed, reduced with T2D, fu-
ture research should be geared toward clarifying this
issue with potential confounding factors like acute and
chronic diet, excess body fatness and the insulinemic
status of the subject taken into account.
Lipid oxidation for subjects with type 2 diabetes during
moderate-intensity exercise
In addition to incremental exercise with multiple stages
to determine the maximal rate of lipid oxidation and
fatmax, fuel use for patients with T2D has also been
assessed during constant-work-rate (CWR) moderate-
intensity exercise and contrasting findings have been
reported. For example, in 1995, Martin et al. found that
during 40 min of cycling at 60% V̇O2max, the hepatic
glucose response was normal (production of ~ 2.4
mmol·min− 1), but arterial glucose had declined (~ 10%)
for non-obese male subjects with T2D compared to
subjects without the disease who experienced an ~ 21%
rise [107]. This greater carbohydrate utilisation was
manifest in a higher RER that was observed during
exercise for the patients with T2D [107]. Five years later,
Blaak et al. used isotope-infusion techniques during 60
min of cycling at 50% V̇O2max to provide further insight.
Specifically, they found a decreased use of
plasma-derived FA during exercise for obese subjects
with T2D compared to age-, weight- and V̇O2max-
matched controls [50]. However, subjects with T2D
demonstrated an increased reliance on IMTG and/or
VLDL such that the whole-body total rate of lipid oxida-
tion during exercise was similar between groups [50].
Employing the same methodology, Mensink et al. con-
firmed similar fat oxidation during exercise for normo-
glycemic obese subjects with impaired glucose tolerance
(i.e., a group at high risk for developing T2D) due to a
‘trend’ (P = 0.07) for a reduced capacity for uptake/oxi-
dation of plasma FA along with an increased reliance on
IMTG- and/or VLDL-derived lipid [108]. However, in a
follow-up study, subjects with T2D who were not obese
(BMI, 28.7 ± 4.2 kg·m− 2) demonstrated similar rates of
total lipid and carbohydrate utilisation during 60min of
cycling at 40% V̇O2max compared to BMI-matched con-
trols [109]. Moreover, no differences were present in up-
take/oxidation of plasma or IMTG-/VLDL-derived lipid
energy although the source of carbohydrate energy was
altered by the disease (lower oxidation of muscle glycogen
and higher plasma glucose use for subjects with T2D)
[109]. This suggests that obesity might exert an influence
on exercise fuel utilisation independent of T2D status
[109]. Finally, Boon et al. also used isotope-infusion
methods for a comparison between ‘long-standing’
obese male patients with T2D and normoglycemic
controls matched for age, sex, body weight and aer-
obic capacity during cycling at 50% WRpeak. These
researchers observed no between-group differences for
total lipid oxidation (~ 40%), IMTG- and/or
VLDL-derived contribution (~ 10%), total carbohy-
drate oxidation (~ 60%) or plasma-glucose/muscle-gly-
cogen contribution (~ 15 and ~ 45%, respectively)
[110]. The reason(s) for this discrepant finding is un-
clear, but might have to do with the duration for
which T2D had been present for the tested subjects.
Specifically, in long-standing patients with T2D,
characteristics of lipid availability/use secondary to
the compensatory hyperinsulinemia that accompanies
IR during earlier manifestation of the disease might
no longer be present [110]. It is also important to
note that the exercise intensities that were assessed in
those studies were different (i.e., 40–60% V̇O2max),
which might also explain equivocal findings (see
section entitled ‘Normalisation of Exercise Intensity
When Assessing Lipid-oxidising Capacity’ below).
Lipid oxidation during exercise for obese subjects
As previously mentioned, ~ 85% of patients with T2D
are also obese; hence, it is not surprising that studies de-
signed to identify the influence of T2D on exercise lipid
use have often been conducted using obese individuals
as subjects. Unfortunately, this makes it difficult to tease
out the independent influence of T2D. Similarly, as a
result of the high prevalence of IR in obese individuals,
investigations designed to determine how obesity influ-
ences exercise substrate use have typically involved
comparisons between groups with differing degrees of
IR. Consequently, the complex influence of IR on exer-
cise fuel use (see below) might also be a confounding
variable in these studies. With this limitation in mind,
the preponderance of evidence suggests that obese indi-
viduals do not differ in their capacity for exercise lipid
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use compared to non-obese control subjects [19, 111–
120] although there are reports of a reduced [121, 122]
or even enhanced [123, 124] capacity associated with the
obese state. Much like was the case with T2D subjects,
the distinction appears to be related to the net effect of
potential alterations in the ability to uptake/oxidise
plasma FA compared to IMTG- and/or VLDL-derived
(i.e., non-plasma) sources. For example, Horowitz et al.
compared lean and abdominally-obese women matched
for V̇O2max during 90 min of moderate-intensity cycling
(~ 54% V̇O2max) and found that the obese subjects
achieved an ~ 25% greater whole-body rate of lipid oxi-
dation despite the fact that whole-body lipolytic activity
and plasma FA oxidation were similar between groups
[123]. This means that the capacity to derive energy
from non-plasma sources (presumably predominantly
IMTG) was greater for the obese subjects [123]. Con-
versely, Goodpaster et al. had obese and lean sedentary
males matched for V̇O2max perform 60min of cycling
(50% V̇O2max) and found that the percentage of plasma
FA oxidation was lower for the obese subjects (51 ± 5 v.
75 ± 10%) [124]. However, despite this impairment,
obese subjects once again derived a greater proportion
of energy from lipid oxidation (43 ± 5 v. 31 ± 2%). An ~
50% greater reliance on non-plasma sources was respon-
sible for offsetting and, indeed, reversing the deficit in
this case [124]. Finally, Mittendorfer et al. compared
lean, overweight and obese subjects during 90min of
cycling (50% V̇O2peak) and also found that the relative
contribution of plasma FA was decreased while the rela-
tive contribution of non-plasma sources was increased
in the obese subjects [115]. However, in this case, the
changes were relatively balanced such that the contribu-
tion of lipid oxidation to total energy transfer (~ 30%)
did not differ between groups [115].
The complex influence of insulin resistance on exercise
fuel use
The potential for IR as a confounding factor in the
aforementioned research is interesting to consider. As
previously mentioned, Robinson et al. found that the
maximal rate of lipid oxidation was positively correlated
with IS in young, healthy, recreationally-active men
[102]. This is consistent with the notion that an im-
paired capacity for exercise lipid oxidation is associated
with the insulin-resistant state. However, this is not a
universal finding. For example, Goedecke et al. assessed
competitive cyclists and found that despite a wide vari-
ation in IS that was present across the group, no correl-
ation between IS and RER at a variety of exercise
intensities was found [125]. Moreover, despite the fact
that both the peak rate of lipid oxidation and fatmax
were higher in overweight subjects with low (0.76 ± 0.02)
compared to high (0.89 ± 0.02) resting RER, Rosenkilde
found that the difference in IS between groups desig-
nated according to that criterion only reached ‘trend’
status (P = 0.09) [126]. Finally, Braun et al. examined ex-
ercise fuel use for overweight or obese women divided
into two groups based on composite insulin-sensitivity
index (IS, 7.7 ± 0.9, IR, 3.0 ± 0.7) during 50 min of cyc-
ling (45% V̇O2peak) and found that RER during the latter
stages of exercise was lower in the IR group [127]. The
authors suggest that this counterintuitive finding reflects
the fact that despite the difference in IR that was present
between the two groups, by design, all subjects were
normoglycemic. Consequently, exercise fuel use was not
confounded by IR-related hyperglycemia and an en-
hanced capacity for glucose movement from blood to
tissues via mass action. In this regard, they suggest that
the concomitant reduction in muscle glycogen use which
they observed for the IR subjects during exercise repre-
sented a ‘downstream’ consequence of initial glycogen
levels that were compromised due to the IR [127]. Un-
fortunately, they did not measure specific lipid sources
during exercise and, therefore, could not confirm that
the decrease in glycogen use and increase in lipid oxida-
tion associated with IR was a function of a greater reli-
ance on IMCL as would be expected [50, 124].
Regardless of this distinction, however, these findings
and those mentioned previously reflect the highly com-
plex nature of IR and suggest that differing degrees of IR
and associated hyperinsulinemia and/or hyperglycemia
might explain the lack of consensus in the literature re-
garding the influence of T2D and/or obesity on the cap-
acity for lipid oxidation during exercise.
Normalisation of exercise intensity when assessing lipid-
oxidising capacity
In addition to potential confounding influences of IR
and/or obesity, ambiguity regarding exercise fuel use for
T2D compared to healthy subjects during CWR exercise
could relate to the relative intensity of the exercise chal-
lenge presented to the subjects. In the aforementioned
study, Venables et al. observed considerable inter-subject
variability with fatmax occurring anywhere between 21
and 77% of V̇O2max in their cohort of healthy individuals
[101]. Consequently, a methodology that calls for sub-
jects being compared at the same percentage of V̇O2max
is inherently flawed because it virtually ensures that
some subjects will be working in proximity to their max-
imal rate of lipid oxidation while others will be exercis-
ing far from it. This has resonance because it is now
well established that the metabolic and gas-exchange re-
sponses to exercise exhibit non-linear characteristics
such that a group of subjects working at the same per-
centage of V̇O2max will encounter considerable
inter-subject variability with respect to the physiological
challenge at hand [128–130]. Conversely, assigning
DiMenna and Arad BMC Sports Science, Medicine and Rehabilitation           (2018) 10:21 Page 11 of 23
exercise intensity relative to the point at which the cellu-
lar phosphorylation and redox potentials that drive oxi-
dative metabolism initially become altered during
incremental exercise (i.e., the lactate or gas-exchange
threshold depending upon whether the determination is
made from the blood-lactate or gas-exchange response;
LT or GET, respectively) provides a way to ensure a
more consistent physiological response across subjects
[129, 130]. With respect to exercise fuel use, this is par-
ticularly relevant because LT/GET also represents the
point at which a disproportionate increase in carbohy-
drate compared to lipid use would be expected to occur.
For example, Achten and Jeukendrup found that LT and
fatmax were correlated and, indeed, did not differ in a
group of endurance athletes [131]. While such coinci-
dence might not be the case in ‘normal’ healthy subjects
where fatmax appears to occur at a lower work rate rela-
tive to LT (e.g., at ~ 75% LT; i.e., 48 ± 1 vs. 65 ± 1%
V̇O2max) [101, 132], in lieu of direct measurement of
fatmax, it seems reasonable to suggest that exercise work
rate should be prescribed relative to LT/GET if the goal
is to establish an unbiased comparison of the capacity
for lipid oxidation for patients with T2D, IR subjects and
subjects who are overweight or obese.
Aerobic training to improve lipid-oxidising capacity and
insulin sensitivity
It is well established by both cross-sectional [133, 134]
and longitudinal [135, 136] research that a chronic adap-
tation to aerobic training is an enhanced capacity for
lipid oxidation at a given rate of work. Furthermore, the
athlete’s paradox implies that aerobic training that ‘turns
over’ IMCL on a regular basis allows elevated levels to
be maintained without pathological repercussion. Col-
lectively, these observations suggest that regardless of
the cause/consequence relationship shared by elevated
IMCL and IR, aerobic training could provide an effective
intervention for improving long-term prognosis. How-
ever, longitudinal (i.e., ‘training’) studies designed to test
this hypothesis have returned mixed findings. Import-
antly, it has long been known that IS is improved follow-
ing a single aerobic exercise bout [137–141] with the
time course for dissipation of this acute effect believed
to be 38–72 h [140, 142]. Consequently, to test for a
chronic improvement in IR due to aerobic training, it
has been suggested that post-exercise measurements
should be performed at least 72 h following completion
of the final exercise bout [15]. However, it is intuitive
that the ‘chronic’ effect of exercise training on IS will
also dissipate with time; hence, testing after a period of
inactivity that allows for amelioration of the acute effect
might not allow for accurate quantification of exercise’s
‘long-term’ benefit. Moreover, there is growing appreci-
ation for the clinical importance of changes in
physiology that occur between single bouts of exercise
(i.e., the ‘subacute’ effect) [143]. Hence, with respect to
‘precision medicine,’ transient improvement in IS
secondary to the residual effect of daily or near-daily
exercise might be an important effect to consider.
Quantification of the chronic effect of aerobic training
on IS is also complicated by the fact that the effect ap-
pears indirect because it depends on the reduction in
body fat that often accompanies the training interven-
tion [15]. For example, Segal et al. had lean and obese
men with or without T2D perform four hours of cycle
aerobic training per week for 12 weeks with body com-
position and weight maintained by re-feeding the energy
expended during each session and found that despite an
~ 27% increase in V̇O2max, IS was not altered in any
group [144]. Similarly, Ross et al. compared a group of
obese men performing aerobic training (walking/jogging
that used 700 kcal per session each day for 12 weeks)
with weight loss allowed to a group performing the same
aerobic training without weight loss and found an ~ 16%
increase in V̇O2peak for both groups [145]. However, IS
was only improved for the group that also lost weight
and, indeed, the magnitude of this improvement (~ 60%)
did not differ compared to that which was achieved in a
third group that experienced the same amount of weight
loss due to dietary restriction with no exercise training
[145]. While this might be interpreted as evidence that
similar metabolic benefit can be gleaned from weight
loss regardless of whether it is precipitated by a dietary-
or exercise-induced negative energy balance, it is im-
portant to note that despite similar reductions of body
weight in both weight-loss groups (~ 8% of initial body
mass), the aerobic-training weight-loss group experi-
enced a greater loss of body fat (~ 1.3 kg), which might
provide long-term benefit [145].
Further evidence that weight loss is the key that drives
a chronic reduction in IR comes from Schenk et al. who
confirmed similar IS improvement alongside an ~ 12%
loss of body fat in abdominally-obese women regardless
of whether the loss was induced either exclusively by
dietary restriction (~ 500–800 kcal/day) or via the same
dietary protocol along with aerobic training (45 min of
cycling at 85% of the maximum heart rate four days per
week) [146]. Interestingly, in addition to an ~ 25% in-
crease in V̇O2peak that differentiated trained from
diet-only groups in this study, the similar effect on IS
was present even though the trained subjects experi-
enced an ~ 20% increase in resting whole-body fat oxida-
tion [146]. Finally, we recently exposed overweight/
obese African American women to a regimen involving
a 24-min high-intensity interval-training (HIIT) bout on
a cycle ergometer performed three times per week with
rigorous control of energy balance to ensure weight
stability throughout the 14-week intervention and
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confirmed no increase in IS due to the exercise training
[147]. This has resonance because both GET and fat
oxidation at a given submaximal rate of work were
improved by the intervention [147].
In addition to improving V̇O2peak/max [144–146] and
lipid-oxidising capacity in the resting state [146] and
during exercise [147], there is evidence to suggest
that weight-stable aerobic training that does not in-
crease IS can favorably alter the composition of lipid
deposition. For example, in the study detailed above,
Ross et al. showed that aerobic training without
weight loss resulted in a reduction in total abdominal
fat although not to the same extent as the diet-only
and diet-plus-exercise weight-loss groups [145]. Fur-
thermore, Devries et al. had obese and lean sedentary
women perform 12 weeks of aerobic training that in-
creased V̇O2peak and lipid-oxidising capacity in both
groups and found that while aerobic training did not
alter total IMCL content, it did change the character-
istics of IMCL accumulation [19]. Specifically, the
percentage of IMCL in direct contact with mitochon-
dria was greater after training because stores were
redistributed from subsarcolemmal to intermyofibrillar
mitochondrial region [19]. This relocation might be
responsible for non-pathological compared to patho-
logical IMCL deposition (i.e., the athlete’s paradox; el-
evated lipid stores that are ‘turned over’ on a regular
basis compared to elevated stores that are not). How-
ever, aerobic training did not precipitate weight loss
in that study; hence, consistent with the aforemen-
tioned observations, IS was not improved even in the
obese subjects who demonstrated greater IR and fast-
ing plasma insulin in the pre-training measurements
[19]. Finally, in a subsequent study, Ross and col-
leagues found that 14 weeks of daily weight-stable aer-
obic training (500 kcal expended per session) reduced
total (~ 7%), abdominal (~ 10%) and visceral (~ 18%)
adipose deposition with no change in IS [148].
Importantly, these improvements were similar to
those observed in a diet-induced weight-loss group
that lost ~ 6.5% of body weight. Furthermore, when
equivalent weight loss was precipitated by AT, the
improvements in IS (~ 32%) and total (~ 18%) and
abdominal (~ 20%) fat were greater compared to those
induced by the diet-only intervention [148]. The
authors concluded that regardless of the effect on IS,
aerobic training without weight loss provides a useful
strategy for reducing total and abdominal obesity,
preserving skeletal muscle mass and improving
cardiorespiratory fitness [148].
The ability of weight-stable aerobic training to im-
prove numerous aspects of metabolic function without
altering IS might seem counterintuitive; however, add-
itional findings from Schenk et al. help to clarify the
dissociation. Specifically, unlike resting whole-body lipid
oxidation which only increased in the training group in
that study (see above), FA mobilisation and uptake in-
creased to a similar extent in both groups [146]. This
implies that it is reductions in systemic FA mobilisation/
uptake that play the primary role in the increased IS that
is observed following a weight-loss intervention [146].
These researchers provided further proof by infusing
lipid after the weight loss had occurred to artificially in-
crease FA mobilisation to pre-loss levels to show that
the IS improvement was almost completely reversed in
both groups despite the augmented capacity for lipid
oxidation in the resting state for the trained subjects
[146].
The inability for aerobic training to universally im-
prove IS is also apparent when age-related declines in IS
are considered. For example, Clevinger et al. determined
IS in four groups of subjects divided according to age
and trained status (young or older; sedentary or
endurance-trained) and found that the normal
age-related decline in IS that was present for sedentary
subjects (~ 53%) was also present for trained individuals
[149]. Specifically, despite the fact that trained subjects
demonstrated higher IS in both age groups, an ~ 36%
decline was observed for older (60 ± 1 yr) compared to
younger (29 ± 1 yr) runners [149]. Moreover, in a
subgroup analysis comprising subjects with similar
whole-body adiposity, an age-related decline in IS (~
33%) was only present for the endurance-trained sub-
jects [149]. This further supports the multi-factorial na-
ture of IR and, specifically, how it can be rooted
differently in disparate subject populations.
Type 2 diabetes and excess body-fat deposition
The critical role of weight loss for conveying the im-
provements in IR that occur with chronic aerobic train-
ing underscores the potent effect of excess body-fat
deposition on insulin’s regulatory capacity. However, as
previously stated, while most subjects with T2D are
obese, most obese subjects do not possess T2D despite
alterations in insulin action and blood-glucose control.
Furthermore, there is growing research interest in a sub-
set of obese individuals without T2D who demonstrate
normal IS. However, while the tendency for these ‘meta-
bolically-healthy obese’ individuals to avert the decline
in insulin action associated with excess body-fat depos-
ition is intriguing, it is, perhaps, their ability to maintain
normal IS in the face of the chronic energetic surplus
required to achieve the obese state that is the most
remarkable aspect of this phenotype [42, 43, 50].
At present, criteria used to define the
metabolically-healthy obese state have not been standar-
dised [6] and controversy exists regarding the degree to
which their ‘healthy’ status might simply reflect a
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transient condition; for example, the slower as opposed
to absence of obesity-related progression of metabolic
decline. Consequently, findings from prospective cohort
studies that detail longitudinal outcomes for
metabolically-healthy obese individuals are useful to
consider. In the North West Adelaide Health Study, Ap-
pleton et al. found that ~ 33% of subjects designated as
metabolically-healthy obese at baseline developed meta-
bolic risk and incident T2D during 5.5–10.3 years of
follow-up while ~ 67% maintained metabolic health and,
accordingly, experienced no additional risk for T2D
compared to normal-weight healthy controls [151]. Im-
portantly, for the latter group, in addition to age (≤40
years), the ability to elude the metabolic consequences
of obesity was correlated with lower waist circumfer-
ence, which resonates because central obesity is associ-
ated with the low-grade inflammatory response that is
linked to IR and associated metabolic aberrations (i.e.,
the ‘metabolic syndrome’) [152]. For example, Klöting et
al. compared morbidly-obese (BMI ≥35 kg·m− 2) IS sub-
jects with age-, sex-, fat- and BMI-matched IR individ-
uals and found that increased visceral fat area, increased
macrophage infiltration into omental adipose tissue, en-
larged adipocyte size in both omental and subcutaneous
fat depots and omental adipocyte IR are all associated
with IR obesity [153]. These characteristics were further
related to dysregulation of circulating adipokines and cy-
tokines including decreased adiponectin and increased
progranulin, chemerin, retinol-binding protein-4 and
fetuin-A serum concentrations [153]. Specifically, macro-
phage infiltration and serum adiponectin accounted for
98% of the variation in glucose infusion rate (GIR) during
the hyperinsulinemic euglycemic clamp that was used to
classify the subjects into IS/IR groups [153]. They also
found that estimated hepatic steatosis (the so-called “non-
alcoholic fatty liver disease”) was similar to visceral adi-
pose tissue for predicting the variance in IR, which sup-
ports the well-established link between fat deposition in
the liver and loss of IS [154]. Indeed, there is evidence to
suggest that it is intra-hepatic as opposed to visceral
adipose deposition that is ultimately responsible for the
degree to which IR accompanies obesity [155].
With respect to lifestyle factors, data from the North
West Adelaide Health Study suggest that while the
metabolically-healthy obese phenotype was associated
with lower levels of physical activity compared to
normal-weight healthy subjects, these individuals were
more likely to engage in moderate-to-high-level physical
activity compared to their metabolically at-risk obese
counterparts [151]. This is consistent with evidence from
both cross-sectional and longitudinal studies which con-
firms that higher cardiorespiratory fitness is a character-
istic of the phenotype [156]. However, neither baseline
nor follow-up level of moderate-to-high physical activity
was associated with the ability for obese subjects to
maintain the metabolically-healthy status over time
[151]. This is, perhaps, surprising given the degree to
which aerobic training can favourably alter
fat-deposition pattern even when body weight remains
unchanged (see above) [19, 145, 157, 158]. Future re-
search is required to provide insight on how habitual
physical activity and/or exercise might contribute to
achievement of the metabolically-healthy obese pheno-
type independent of or in concert with other lifestyle
factors (e.g., dietary composition) and genetics.
Metabolically-obese Normal weight
Similar to metabolically-healthy obese individuals, there
is growing research interest in individuals who are of
normal weight, but ‘metabolically obese’ because this
phenotype provides an opportunity to study the meta-
bolic decline that culminates in T2D independent of the
influence of excess body fatness and/or chronic positive
energy balance. In one such study, Scott et al. set out to
determine the role of common genetic variants shown
to be associated with IR in the aetiology of T2D when
obesity is not present and confirmed an association for
genetically-predicted IR with incident T2D completely
independent of BMI [159]. Indeed, this association was
present even in normal-weight subjects with the lowest
waist circumference (< 94.0 and 78.5 cm for male and fe-
male subjects, respectively) [159]. Importantly, these var-
iants are associated with impaired adipose expandability
and ectopic fat accumulation, which means that genetic
scores for IR implicate an impaired capacity to store
lipids in the aetiology of T2D even when obesity and
chronic positive energy balance are not part of the equa-
tion. However, there do appear to be qualitative differ-
ences when the IR-to-T2D pathway is not
complicated by the obese state. For example, in a
recent review article, Stefan et al. determined the de-
gree to which four major risk phenotypes (non-alco-
holic fatty liver disease, visceral adipose tissue, ratio
of subcutaneous abdominal fat mass to total fat mass
and ratio of subcutaneous gluteofemoral fat mass to
total fat mass) might account for the metabolically-
unhealthy normal-weight state in 981 subjects at in-
creased risk of cardiometabolic disease based upon
body weight, FH+ status, elevated blood glucose level
or a history of gestational diabetes in women [11]. In
addition to identifying the prevalence of these pheno-
types in metabolically-unhealthy normal-weight indi-
viduals compared to normal-weight healthy subjects,
these authors also sought to discover how their influ-
ence might differ compared to that which is present
with the overweight/obese unhealthy state [11]. As
there is no universal definition of what constitutes
the metabolically-healthy state in the literature, in
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their review, Stefan et al. defined it as one for which
fewer than two parameters of the metabolic syndrome
were present. These researchers found that compared
to metabolically-healthy normal-weight individuals,
the most prevalent risk phenotype for a reduction in
metabolic health for normal-weight individuals was
insulin-secretion failure with these individuals also
more frequently demonstrating IR, non-alcoholic fatty
liver disease, visceral obesity, a low percentage of sub-
cutaneous gluteofemoral fat mass, low cardiorespira-
tory fitness and increased carotid intima-media
thickness (a measure that indicates the extent of ca-
rotid atherosclerotic vascular disease) [11]. Import-
antly, a number of these characteristics contrasted
what was observed for metabolically-unhealthy over-
weight/obese subjects who demonstrated weaker in-
creases in the prevalence of IR, low percentage of
subcutaneous leg fat mass and impaired cardiorespira-
tory fitness with stronger increases in the prevalence
of non-alcoholic fatty liver disease and visceral obes-
ity. These findings regarding differences in body-fat
compartmentalisation are particularly intriguing be-
cause the optimal pharmaceutical treatment strategy
in this case (i.e., drugs that promote adipocyte differ-
entiation to address the impaired capacity for expan-
sion of subcutaneous adipose tissue in the lower
body) would be different compared to what might be
employed for metabolically-unhealthy obese patients
[11]. However, the researchers warn that they only
assessed Caucasians in this study, which is important
because compared to Caucasians (21.0%), the
metabolically-unhealthy normal-weight phenotype is
more prevalent in Chinese Americans (32.2%), African
Americans (31.1%), Hispanics (38.5%) and South
Asians (43.6%) [157]. Moreover, they only included
middle-aged subjects. Consequently, findings from
this study might not be reflective of what would be
present in other ethnic or age groups. Nevertheless,
these results confirm that the pathway to T2D can be
different for predisposed individuals when excess
body-fat storage and chronic positive energy balance
are not part of the sequela.
Exercise as medicine for type 2 diabetes
In 2010, the ACSM and the American Diabetes Associ-
ation (ADA) issued a joint position statement that in-
cluded a review of the research concerning how exercise
or physical activity might positively affect physical fit-
ness, morbidity and mortality in individuals with T2D
[20]. Importantly, the statement delineates acute from
chronic training effect by recognising that mild- and
moderate-intensity exercise can result in transient im-
provements in systemic insulin action and, by extension,
blood-glucose control from 2–72 h post exercise [20].
The time course of this improvement appears to be re-
lated to both the duration and intensity of the preceding
exercise bout with age, pre-exercise level of control and
state of physical training also playing a role [20]. Fur-
thermore, with respect to this acute effect, a combin-
ation of aerobic training and resistance training might
be more effective for blood-glucose management in
patients with T2D compared to either type of exercise
performed exclusively [20]. However, the degree to
which positive findings regarding such ‘combination
training’ reflect a synergistic effect due to disparate
training adaptations (e.g., enhanced peripheral insulin
action due to aerobic training plus augmented glucose
storage due to resistance training) as opposed to simple
volume differences remains to be clarified [20]. Never-
theless, data from two recent systematic reviews and
network meta-analyses provide compelling evidence that
combining the two types of exercise training is the best
strategy for patients with or at risk for T2D. For
example, a program that combines aerobic and resist-
ance training is superior for favourably altering body
composition in overweight/obese subjects because aer-
obic training results in a more pronounced reduction of
body weight, waist circumference and fat mass while re-
sistance training elicits a greater increase of lean body
mass [160]. Furthermore, for patients with T2D, combin-
ing the two forms of training brings the greatest reduc-
tion in HbA1c, fasting glucose, triaglycerols,
high-density lipoproteins, diastolic blood pressure and
body weight compared to either type of exercise per-
formed exclusively [161]. However, with respect to these
findings, the authors warn that interpretation with re-
gard to clinical relevance is limited by the
low-to-moderate quality of the included studies and the
amount of information provided on clinically-important
outcomes and adverse effects of exercise [161].
With respect to chronic improvements in disease
prognosis for patients with T2D, the position statement
recognises that exercise training can elicit positive adap-
tations that result in improved insulin action,
blood-glucose control and muscle-lipid characteristics
[20]. Specific training-induced adaptations suggested to
be beneficial in this regard include enhanced expression
and/or activity of proteins involved in glucose metabol-
ism and insulin signaling (e.g., glycogen synthase,
GLUT4), improved capacity for lipid oxidation and in-
creased IMCL storage [20]. Once again, the role that re-
sistance training and resultant muscular hypertrophy
might play in addition to traditionally-prescribed aerobic
training is mentioned [20]. For example, Bweir et al.
found that a group of patients with T2D experienced a
greater decrease in hemoglobin A1c after 10 weeks of
progressive resistance training compared to the decrease
due to treadmill training that required the same
DiMenna and Arad BMC Sports Science, Medicine and Rehabilitation           (2018) 10:21 Page 15 of 23
heart-rate response (60–75% maximum) for age- sex-
and disease-matched subjects (an ~ 18 and ~ 8% de-
crease, respectively) [162]. These findings support the
contention that an exercise program designed to chron-
ically improve blood-glucose control for patients with
T2D should include a resistant-training component [20].
In addition to explaining modes of exercise that can
benefit patients with T2D, the ACSM/ADA position
statement includes specific recommendations regarding
exercise prescription. For example, for aerobic training,
the recommendation is for patients with T2D to perform
at least 150 min per week; specifically, three weekly ses-
sions with no more than 48 h interspersed [20]. The ob-
jective of this high-frequency paradigm is to ensure that
the acute increase in insulin action that follows an
aerobic-training session is in effect continuously. It is
suggested that aerobic training be of at least moderate
intensity (40–60% V̇O2max) although additional benefit
might be attainable with vigorous efforts (> 60% V̇O2max)
[20]. For example, a meta-analysis by Boulé et al. sug-
gests that aerobic-training intensity predicts the
post-intervention improvement in hemoglobin A1c to a
larger extent compared to volume of aerobic training
performed [163]. With regard to resistance training, the
recommendation is for at least two, but ideally three
weekly sessions on non-consecutive days using either
moderate or heavier loads (i.e., 50% or 75–80% of the
one-repetition maximum weight, respectively) with the
latter considered optimal for improvements in strength
and insulin action [20]. The resistance-training protocol
should include at least 5–10 exercises involving the
major muscle groups with sets continued to near failure
(e.g., starting at 10–15 repetitions and progressing over
time to 8–10) [20]. It is recommended that one set will
suffice, but as many as four might be optimal for
strength gain [20]. Finally, patients with T2D are advised
to increase their total daily unstructured physical activity
to assist in the control of body weight [20]. This is im-
portant because it is well established that individuals
with T2D engage in less physical activity; for example, a
survey of the US population in 2003 revealed that only
39% of adults with diabetes were physically active com-
pared to 58% of healthy counterparts [59]. Moreover, re-
cent accelerometer data confirms lower total activity
counts for older individuals (> 60 years) with T2D com-
pared to older subjects with normal blood-glucose levels
[60]. Whether this reduction is a cause or consequence
of T2D cannot be ascertained from this cross-sectional
study; however, it is interesting to note that subjects di-
agnosed with prediabetes demonstrated similar total ac-
tivity counts compared to healthy controls [60]. It has
also been shown that in addition to a reduction in the
total amount of physical activity, individuals with T2D
appear to engage in lower-intensity efforts compared to
healthy subjects [61]. Collectively, these related to phys-
ical activity facilitate the positive energy balance and as-
sociated metabolic decline that is typically present for
patients with T2D [150].
The joint position statement regarding exercise and
T2D also provides evidence statements concerning phys-
ical activity as an intervention to prevent or delay the
onset of T2D in at-risk subjects without the disease. For
example, in a population-based prospective study, Wei
et al. assessed 8633 individuals without diabetes at least
twice and found that during an average follow-up visit
after six years, 149 had developed T2D while 593 had
developed impaired fasting glucose [164]. After age,
cigarette smoking, alcohol consumption and parental
diabetes were considered, the least fit 20% of the cohort
according to treadmill V̇O2max at baseline had a 1.9-fold
risk for impaired fasting glucose and 3.7-fold risk for
T2D compared to the most fit 40% of the cohort. Age,
BMI, blood pressure, triglyceride level, and FH+ status
were also directly related to the risk of developing T2D
[164]. Similar results were observed when the Diabetes
Prevention Program Research Group conducted a large,
randomised clinical trial involving US adults at high-risk
for T2D. Specifically, these researchers exposed 1079
subjects that did not possess T2D but did demonstrate
elevated plasma glucose during fasting and two hours
after a 75-g oral glucose load to a longitudinal
lifestyle-intervention program that included 150 min of
physical activity per week. The program was designed to
facilitate weight loss of ~ 7% and subjects in this group
were compared to similar subjects treated with a
blood-glucose control medication (metformin) or pla-
cebo [165]. Throughout an average follow-up period of
2.8 years, the cumulative incidence of T2D was lower
compared to placebo in both intervention groups;
however, the reduction was greater with the
lifestyle-intervention strategy (58 vs. 31%) [165]. Indeed,
lifestyle intervention prevented one case of T2D per
seven persons treated for three years and, importantly,
this preventative effect was similar in both sexes, for all
ethnicities and in older subjects [165]. Unfortunately,
given the methodology, teasing out the independent
effect of increased physical activity compared to those of
dietary changes and weight loss was not possible. How-
ever, after reviewing all of the relevant research, authors
of the position statement suggest that physical activity
seems to play a role in preventing T2D across ethnic
groups and in both sexes and provide further clarifica-
tion by stressing that this applies to moderate-intensity
aerobic training while the role of resistance training in
preventing T2D has not yet been investigated [20]. They
conclude with an evidence statement which indicates
that at least 2.5 h/week of moderate to vigorous physical
activity should be undertaken as part of lifestyle changes
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that are appropriate for T2D prevention in high-risk
adults [20].
The key variable for prescribing exercise as precision
medicine for insulin resistance
The ACSM/ADA joint position statement provides im-
portant evidence-based recommendations that can help
to inform the design of exercise-training regimens for
patients with T2D and at-risk individuals [20]. However,
if exercise is to truly be considered as medicine for treat-
ing the underlying cause of T2D, greater detail is neces-
sary. Specifically, consistent with the concept of
‘precision medicine’ [166], it stands to reason that when
exercise is prescribed as a treatment modality, program
variables should be determined precisely in accordance
with specific characteristics of the individual. Of particu-
lar import in this regard is determination of intensity of
effort, which might very well represent the key variable
when prescribing exercise as medicine for IR. Specific-
ally, it is conceivable that three distinctly different inten-
sity paradigms could be optimal for treating IR and
delaying/preventing its progression to T2D. For ex-
ample, if a mitochondrial defect predisposes the patho-
logical progression, an exercise intensity that maximises
improvements in mitochondrial function would be war-
ranted. There is a growing body of research which sug-
gests that HIIT is specific for this purpose [167, 168].
This approach, which provides a time-efficient way to
rapidly improve insulin action for patients with T2D and
prediabetes [169], involves periods of high-intensity
(HIIT) or all-out (sprint-interval training; SIT) exercise
interspersed with periods of rest or low-intensity effort.
However, while this type of exercise would maximise
peripheral stimulation, the contribution of lipid to
exercise fuel use at this intensity would be negligible
(Fig. 3). Conversely, if mitochondrial function is suffi-
cient [63] and ectopic fat accumulation is at the root of
the pathology, a low-intensity approach that allows the
maximal rate of lipid oxidation to be sustained might be
preferred to maximally perturb the IMCL pool [101,
170–172] and/or change its relationship with muscle
mitochondria [19]. Indeed, such a protocol has been
used to improve the ability to oxidise lipid during exer-
cise for patients with T2D [173]. Finally, if weight loss is
the ultimate objective of the training, exercise at the
maximum sustainable pace (e.g., at a metabolic rate that
exceeds that which allows for the maximal rate of lipid
oxidation, but is aligned with the work-rate/time asymp-
tote for high-intensity exercise; i.e., the ‘critical power/
velocity’) would provide for the duration/intensity inter-
action that results in the greatest energy use. This
approach might also be preferred because a program for
obese women with metabolic syndrome that included
CWR walk/running at a work rate situated midway be-
tween that which is aligned with LT and V̇O2peak (i.e., at
50%Δ, which would, on average, be in proximity to the
critical velocity [174]) reduced total and subcutaneous
abdominal fat and visceral adipose tissue while one that
involved walk/running at/below LT with similar energy
expenditure (~ 2000 kcal/wk) did not [175]. The rea-
son(s) for this difference despite similar energetic outlay
is/are unclear, but might have to do with greater
post-exercise energy expenditure and fat oxidation due
to an intensity-driven release of lipolytic hormones (e.g.,
growth hormone and epinephrine) [175].
With respect to determining the intensity of effort that
is optimal for delaying/preventing the progression of IR




















Fig. 4 Three distinctly different intensity paradigms that could be optimal for preventing/treating insulin resistance and its progression to type 2
diabetes. Constant-work-rate exercise at the ‘fatmax’ would allow for the highest rate of lipid turnover while constant-work-rate exercise at the
‘critical power’ would result in the greatest sustainable rate of energy use. Even higher intensities can be achieved by employing high-intensity
interval training; however, in this case, intermittent periods of rest or low-intensity exercise must be interspersed to allow the exercise bout to be
continued. See text for further details regarding advantages and disadvantages of each of these approaches
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three distinctly different approaches (see Fig. 4). Conse-
quently, more research to compare these training para-
digms in different types of at-risk subjects and at
different points of disease progression are warranted.
However, another possibility is that a program that com-
bines all three types of aerobic training on different days
of a training cycle might be best suited for spanning the
range of adaptations that could improve prognosis.
Interestingly, such a ‘periodised’ approach to training has
long been a staple of the programs followed by endur-
ance athletes that might typically involve ‘easy,’ ‘steady,’
‘tempo’ and high-intensity-interval training over the
course of a week [176]. The degree to which such an ap-
proach is both effective and safe for individuals with IR/
T2D requires future research attention.
Conclusion
The cause/consequence characteristics of the relationship
between pathological fat deposition and/or mobilsation, ele-
vated and/or poorly-distributed IMCL, compromised mito-
chondrial structure and/or function, an altered ability to
use lipid as fuel and IR remains to be clarified (see Fig. 5).
However, the well-established association between IR and
the pathological progression to T2D in both obese and
normal-weight individuals suggests that a treatment proto-
col should be geared toward both symptom and cause.
With respect to aerobic training and IR, it appears that the
independent effect is predominantly acute; for example, a
48-h increase in IS upon completion of an exercise bout.
However, research also suggests that such exercise can aid
in the achievement of a chronic improvement in IS by fa-
cilitating the negative energy balance needed to elicit the
requisite body-fat loss. Regular exercise training can also
alter lipid-deposition pattern resulting in a more favourable
distribution of both adipose and intramuscular stores.
However, the training intensity/intensities best suited to
precipitate these changes remains to be determined. With
numerous issues still unresolved, further research is re-
quired before exercise can faithfully be prescribed as ‘preci-
sion medicine’ to combat IR and its progression to T2D.
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Fig. 5 Multi-factorial sequence of events that can potentially explain the progression to T2D. It is well established that genetics and/or an
obesogenic lifestyle can precipitate a series of events that culminate in type 2 diabetes. While cause/consequence characteristics continue to be
debated, it is undeniable that impaired insulin action is a key aspect of the pathology with ectopic fat accumulation also playing a central role
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